Sana Biotechnology(US:SANA)2026-03-03 21:11Financial Performance - Reported Q4 2025 cash position of $138.4 million, down from $152.5 million in Q4 2024, primarily due to cash used in operations of $143.8 million[10] - Net loss for Q4 2025 was $58.8 million, or $0.21 per share, compared to a net loss of $49.1 million, or $0.21 per share in Q4 2024[10] - Non-GAAP net loss for Q4 2025 was $44.7 million, or $0.16 per share, compared to $54.8 million, or $0.23 per share in Q4 2024[11] - GAAP net loss for Q4 2025 was $58.825 million, compared to a loss of $49.069 million in Q4 2024, representing a 19% increase in losses year-over-year[25] - For the twelve months ended December 31, 2025, GAAP net loss was $244.166 million, a decrease of 8% compared to $266.759 million in 2024[25] Research and Development - Research and development expenses for Q4 2025 were $34.9 million, a decrease of $10.2 million compared to Q4 2024, driven by portfolio prioritization[10] - Research and development expenses for the twelve months ended December 31, 2025, were $131,980 thousand, down from $215,673 thousand in 2024, a decrease of about 39%[18] - Significant progress made in developing SC451 and SG293, with both therapies expected to enter clinical trials this year[3] - Expected to file investigational new drug application (IND) for SC451 in type 1 diabetes and begin Phase 1 trial as early as this year[1] - Anticipated first-in-human data for SG293 in blood cancers as early as this year, demonstrating deep B-cell depletion in preclinical studies[1] Cash Flow and Expenses - Non-GAAP operating cash burn for 2025 was $138.5 million, down from $195.1 million in 2024[10] - Operating cash burn for the twelve months ended December 31, 2025, was $(138,519) thousand, compared to $(195,110) thousand in 2024, reflecting a reduction of approximately 29%[23] - Total operating expenses for the twelve months ended December 31, 2025, were $250,319 thousand, down from $272,723 thousand in 2024, representing a reduction of about 8%[18] - General and administrative expenses for the twelve months ended December 31, 2025, were $44,296 thousand, down from $64,040 thousand in 2024, a decrease of about 30.9%[24] Assets and Liabilities - Cash, cash equivalents, and marketable securities decreased from $152,497 thousand in 2024 to $138,382 thousand in 2025, a decline of approximately 9%[16] - The total liabilities increased slightly from $250,516 thousand in 2024 to $256,006 thousand in 2025, an increase of approximately 2.2%[16] - The total stockholders' equity decreased from $250,504 thousand in 2024 to $160,884 thousand in 2025, a decline of about 36%[16] Shareholder Information - The company reported a weighted-average number of common shares of 253,234 for the twelve months ended December 31, 2025, compared to 230,891 in 2024, an increase of approximately 9.6%[18] - Weighted-average shares outstanding increased to 275,882 in Q4 2025 from 236,299 in Q4 2024, reflecting a 17% increase[25] Impairment and Fair Value Adjustments - Non-cash impairment of long-lived assets for 2025 was $44.6 million, significantly higher than $1.9 million in 2024, related to manufacturing facilities[10] - The estimated fair value of success payment liabilities resulted in an expense of $5.1 million for Q4 2025, compared to a gain of $9.2 million in Q4 2024[25] - The contingent consideration related to the acquisition of Cobalt contributed to the financial adjustments, with a change in estimated fair value of $8.577 million for Q4 2025[26] - The total expense related to the Cobalt success payment liability for the twelve months ended December 31, 2025, was $13.6 million, compared to a gain of $6.9 million in 2024[25] - Impairment of long-lived assets was recorded at $1.891 million for Q4 2024, while no impairment was reported for Q4 2025[25] - Personnel-related costs incurred in connection with portfolio prioritization were $5.840 million in Q4 2024, with no such costs reported in Q4 2025[25]